FDA label
What is Bevespi Aerosphere used for?
Bevespi Aerosphere contains glycopyrrolate and formoterol. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Bevespi Aerosphere?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Bevespi Aerosphere, aerosol, metered
Indications and Usage, quoted from the label by AstraZeneca Pharmaceuticals LP (NDA208294). Cross-references to other label sections are left out.
BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Limitations of Use:
BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma.
Source: DailyMed label, set id ae02436e-9528-490e-a844-0c0f6f2843f9, version 26, effective March 24, 2023. NDC 0310-4600, one of 1 listing for this product.
Questions
What is Bevespi Aerosphere used for?
The FDA label says: “BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).”
What drug class is Bevespi Aerosphere?
FDA lists glycopyrrolate and formoterol in the Anticholinergic and Cholinergic Muscarinic Antagonist and beta2-Adrenergic Agonist established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.